Latest news

Nanologica AB (publ) Enters the Insulin Market in China

1 October, 2025

Nanologica has entered the insulin market in China with an order of approximately SEK 2 million for the company’s silica-based purification media NLAB Saga®. The customer is an insulin manufacturer and the order relates to evaluation of NLAB Saga® on a production scale. This is Nanologica’s first order regarding evaluation of NLAB Saga® for insulin manufacturing on the Chinese market. Nanologica’s team has worked with this customer for a few years and the customer has

CEO Andreas Bhagwani presents at Redeye Theme Event Tools and Supplies in Life Science 2025

23 September, 2025

CEO Andreas Bhagwani presents at Redeye Theme Event Tools and Supplies in Life Science 2025 – September 23.

Nanologica presents at Redeye Theme: Tools and Supplies in Life Science

22 September, 2025

Nanologica’s CEO Andreas Bhagwani presents at Redeye Theme: Tools and Supplies in Life Science on September 23. The time for the presentation is 9.35.

CEO COMMENT Q2 2025

11 July, 2025

As expected, the second quarter was not as strong in terms of sales as the first. However, we are making clear progress in our work to streamline the production process, which will generate positive effects over time. We also received our first order from the US for testing NLAB Saga® on a production scale. The company’s top priority continues to be the production of NLAB Saga®. During the quarter, we have introduced techniques to increase

Intervju med vd Andreas Bhagwani efter delårsrapporten för Q2

10 July, 2025

Number of Shares and Votes in Nanologica AB (publ)

30 June, 2025

The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5. In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May 21, 2025, holders of warrants of series TO5 have had the right to subscribe for shares by virtue of warrants.

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive